Raja Mehanna is a Neurology physician affiliated with The University of Texas Health Science Center. OpenAlex indexes 84 publications with 1,667 citations (h-index 20); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
6410 Fannin St
Suite 1014
Houston, TX 770303000
Telephone
832-325-7080Registry record last updated 2 Aug 2016.
Clinical trials
- Utilization of Target Ranges to Treat Persons With Parkinson's Disease by Objective Measurement Using the PKG
Sponsor: Global Kinetics Corporation
- Utilization of Target Ranges to Treat Parkinson's Disease With the PKG
Sponsor: Global Kinetics Corporation
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
37 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Abbott LaboratoriesProgram year20259 payments
- ABBVIE INC.Program year202525 payments
- Medtronic, Inc.Program year20255 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
92.2%Aromatic Amino Acid Decarboxylation Inhibitor31%Carbidopa-Levodopa70%Rytary15%Carbidopa-Levodopa Er9%Carbidopa-Levodopa-Entacapone7%Part D<11 patientsSSRI8.7%Escitalopram Oxalate55%Fluoxetine Hcl26%Sertraline Hcl19%Part D<11 patients+ 16 more classes in this area
Musculoskeletal
3%Neuromuscular Blocker2%Botox100%Part D≥12 patientsgamma-Aminobutyric Acid-ergic Agonist1%Baclofen100%Part D<11 patientsCardiovascular
2.9%Beta blocker2.9%Propranolol Hcl Er59%Propranolol Hcl41%Part D≥14 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Diagnostic work up when suspecting early onset Parkinson disease (EOPD). Recommendations from the MDS EOPD study group
Parkinsonism & Related Disorders
2025 - Endothelial dysfunction in psoriatic arthritis patients: relation to serum uric acid and disease activity
The Egyptian Journal of Internal Medicine
2025 - Systemic Symptoms in Huntington's Disease: A Comprehensive Review
Movement Disorders Clinical Practice
2024 - Valbenazine for the treatment of chorea associated with Huntington’s disease
Expert Opinion on Pharmacotherapy
2024 - Unmet Need in Early-Onset Parkinson’s Disease: Deep Brain Stimulation and Pregnancy
Journal of Parkinson s Disease
2024
Similar KOLs
Other experts from the same institution or the same specialty.
John Reveille, MD
The University of Texas Health Science Center
Hazim Safi, MD
The University of Texas Health Science Center
Jimmy Espinoza, MD
The University of Texas Health Science Center
Adelaide Hebert, MD
The University of Texas Health Science Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”